Thông tin thuốc gốc
Chỉ định và Liều dùng
Resistant partial epilepsy with or without secondary generalisation
Adult: As an adjunct: 1 g daily, increase in increments of 0.5 g wkly. Max: 3 g daily in 1-2 divided doses.
Child: As an adjunct: Initially, 40 mg/kg daily, followed by the following maintenance dose: 10-15 kg: 0.5-1 g/day; 15-30 kg: 1-1.5 g/day; 30-50 kg: 1.5-3 g/day; >50 kg: 2-3 g/day. Doses to be admin once or twice daily.
Elderly: Dose reduction may be needed.

Infantile spasms
Child: As monotherapy: 50 mg/kg daily, adjust according to response over 7 days. Max: 150 mg/kg daily in 1-2 divided doses.
Renal Impairment
<60 ml/min: Dose reduction may be needed; monitor for sedation or confusion.
Cách dùng
May be taken with or without food.
Chống chỉ định
Lactation, preexisting visual field defects, known hypersensitivity.
Thận trọng
History of psychosis, depression or behavioural problems; preexisting clinically significant visual field defect. Visual field function should be assessed at baseline and every 6 mth during treatment. Closely monitor neurological function. Patient to report any new visual symptoms during therapy. Avoid rapid withdrawl, taper over 2-4 wk. May worsen absence seizures. May impair ability to drive or operate machinery. Impaired renal function. Pregnancy, elderly.
Phản ứng phụ
Drowsiness, fatigue, dizziness, nervousness, irritability, headache, confusion, depression, aggression, psychosis, excitation and agitation in child, memory disturbance, irreversible visual field defects, diplopia, weight gain, GI disturbances, ataxia, paraesthesia, tremor, inability to concentrate, hepatitis. Decreased LFT, haemoglobin.
Quá liều
Symptoms: Drowsiness, vertigo, headache, psychosis, respiratory depression, apnoea, bradycardia, hypotension, agitation, irritability, confusion, abnormal behaviour, speech disorder and coma. Management: Treatment is supportive.
Tương tác
Decreased phenytoin levels with concurrent use. Small decrease in phenobarbital levels with concurrent use.
Lab Interference
May give false positive test for certain rare genetic metabolic disorders as it increases the amount of amino acids in the urine.
Tác dụng
Description: Vigabatrin, an analogue of gamma-aminobutyric acid (GABA), is an irreversible inhibitor of GABA-transaminase. It is used in patients with resistant partial epilepsy (with or witho secondary generalisation) as an adjunctive antiepileptic and for unresponsive therapy. It is also used as monotherapy for infantile spasms. No correlation between plasma concentration and efficacy. Duration of drug effect depends on GABA transaminase re-synthesis rate.
Absorption: Rapid and completely absorbed from GI tract. Food does not affect absorption.
Distribution: Widely distributed. Not protein bound. Plasma and CSF concentrations increase linearly over recommended dose range.
Metabolism: Not metabolised.
Excretion: Excreted as unchanged drug in urine (70% of dose). No metabolites identified. Terminal half life: 5-8 hr.
Phân loại MIMS
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Vigabatrin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Sabril
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in